

Vaccibody AS - Notice of Annual General Meeting on 5 May 2021

Oslo, Norway, April 28, 2021 – the Board of Directors of Vaccibody AS, a clinical-stage biopharmaceutical company dedicated to the discovery and development of vaccines and novel immunotherapies, hereby calls for the Annual General Meeting at meeting room Toppcenteret - FAROS - Building H, Plan 5 in Gaustadalléen 21, Oslo, Norway at 10:00 CET on May 5, 2021. All documents regarding the Annual General Meeting are available at the Company's website: <https://www.vaccibody.com/annual-general-meeting/>

As a consequence of the extraordinary situation related to the corona virus, the Board encourages shareholders not to attend the general meeting in person, but rather to make use of the ability to vote by proxy. The proxy form will be found at the above weblink.

For further information, please see the Company's website or contact Chairperson Anders Tuv. Please see below for contact details.

About Vaccibody

Vaccibody AS, is a clinical-stage biopharmaceutical company, dedicated to the discovery and development of vaccines and novel immunotherapies. The Company develops vaccines for the treatment cancer and infectious diseases. Vaccibody's vaccine technology specifically targets antigens to Antigen Presenting Cells, which are essential for inducing rapid, strong and long-lasting antigen-specific immune responses and elicit efficacious clinical responses. Its lead product candidates include VB10.NEO, a cancer neoantigen vaccine, which is exclusively outlicensed to Genentech and is in phase I/IIa clinical trial for the treatment of melanoma, lung-, head and neck, renal-, and bladder cancer; and VB10.16, a therapeutic vaccine for the treatment of human papilloma virus 16 induced malignancies, such as cervical cancer and cancer of the head & neck. Further, the Company has collaborations with Roche and Nektar Therapeutics within oncology.

Additionally, Vaccibody intends to leverage the potential of its platform in infectious disease indications, including its second-generation COVID-19 vaccine program, VB10.COVID.

Vaccibody's shares are traded on Euronext Growth (Oslo), a trading platform operated by Euronext, the leading Pan-European market infrastructure. The ticker code is VACC. Further information about Vaccibody may be found at <http://www.vaccibody.com>

Contact for Vaccibody:

Chairperson Anders Tuv
Vaccibody AS
Cell: +47 982 06 826
atuv@vaccibody.com

Vaccibody AS

Oslo Research Park
Gaustadalléen 21
0349 Oslo, Norway

Forward-looking statements for Vaccibody

This announcement and any materials distributed in connection with this announcement may contain certain forward-looking statements. By their nature, forward-looking statements involve risk and uncertainty because they reflect the company's current expectations and assumptions as to future events and circumstances that may not prove accurate. A number of material factors could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements.